Full-Time

Director Clinical Supplies & Logistics

Updated on 9/4/2026

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

$199k - $258k/yr

+ Discretionary annual bonus + Long-term incentive award/equity

Remote in USA

Remote

Periodic travel to Beeline Medicines offices is required.

Bachelor's, Master's, MBA

Category
Operations & Logistics (2)
,
Required Skills
Forecasting
Google Cloud Platform

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • A bachelor's degree is required in Supply Chain Management, Life Sciences, Engineering, Pharmacy, or a related discipline.
  • At least 10 years of clinical supply chain experience in the pharmaceutical or biopharmaceutical industry, including at least 3 years in a leadership role with direct accountability for global clinical supply operations.
  • Demonstrated expertise in end-to-end clinical supply chain management, including demand planning, investigational medicinal product packaging and labeling, IRT/IVRS systems, global distribution, cold chain logistics, and depot management.
  • Deep knowledge of global GMP, GDP, and GCP regulations applicable to clinical supply chain operations, including FDA 21 CFR Parts 211/312, EU GMP Annex 13, and ICH E6(R2), as well as familiarity with country-specific import/export requirements across clinical geographies.
  • Familiarity with clinical supply chain management for both small molecules and biologics/large molecules, including cold chain and stability considerations for protein-based therapeutics.
  • Proficiency with supply chain management tools, ERP/CTMS systems, and clinical supply planning platforms.
  • A track record of building clinical supply chain infrastructure, SOPs, and operational processes in a pre-commercial or rapidly scaling biotech organization.
  • Demonstrated ability to lead through influence in a matrixed organization, aligning Clinical Operations, CMC, Quality, Regulatory, and Finance stakeholders around supply chain priorities without direct authority over all constituents.
  • A proven track record of operating effectively in pre-commercial, resource-constrained environments while building clinical supply infrastructure and executing active trial timelines.
  • Experience serving as an operational and strategic partner to senior leaders, with the credibility and judgment to escalate supply risks, recommend course corrections, and drive rapid resolution.
  • Strong written communication skills, including experience producing supply chain status reports, risk registers, executive summaries, and regulatory-facing supply documentation.
  • Experience facilitating cross-functional supply chain review meetings, risk escalation discussions, and vendor business reviews.
Responsibilities
  • Design and lead the end-to-end clinical supply chain strategy for all active and planned clinical programs, including demand forecasting, inventory planning, clinical packaging and labeling, IRT/IVRS configuration, distribution, and returns/destruction.
  • Own the global investigational medicinal product distribution network, including selection and governance of third-party logistics providers, cold chain carriers, and depot partners across North America, Europe, and other global regions.
  • Ensure temperature-controlled supply chain integrity from contract development and manufacturing organization release through clinical site delivery.
  • Serve as the primary supply chain interface to Clinical Operations and integrate clinical supply timelines into study startup plans, protocol amendments, site activation milestones, and enrollment projections.
  • Lead clinical supply planning and demand forecasting across concurrent trials using IRT/IVRS data and enrollment modeling to optimize inventory, minimize waste, and prevent supply disruptions.
  • Oversee clinical packaging, labeling, and secondary manufacturing activities at contract development and manufacturing organization and contract manufacturing organization sites, ensuring compliance with country-specific labeling, GMP, and blinding requirements.
  • Manage import/export logistics and global trade compliance for investigational medicinal product shipments across active clinical geographies, including regulatory import permits, customs documentation, and country-specific distribution authorizations.
  • Establish and govern relationships with contract development and manufacturing organizations, third-party logistics providers, comparator drug suppliers, and specialty logistics vendors; define performance expectations, conduct business reviews, and manage escalations.
  • Partner with Quality Assurance to ensure clinical supply chain operations meet GDP/GMP requirements and lead or support regulatory inspections, internal audits, and contract development and manufacturing organization quality reviews.
  • Build and maintain clinical supply chain SOPs, batch disposition records, chain-of-custody documentation, and reconciliation processes aligned with ICH E6 (GCP), GMP, and GDP expectations.
  • Author and update pharmacy manuals, Investigator Brochure supply sections, and site handling guidance to ensure clinical site readiness.
  • Lead investigations of supply chain exceptions and deviations, including root cause analysis, CAPA development, implementation, and closure; ensure supply-related non-conformances are resolved and escalated appropriately.
Desired Qualifications
  • An advanced degree such as a Master of Science, Master of Business Administration, or equivalent is strongly preferred.
  • Collaborative communication style and the ability to build credibility and trust quickly across scientific, clinical, operational, financial, and external partner stakeholders.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...